Gloria Taliani

Prof. Dr. Gloria Taliani

Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 1991 in The Lancet
Verified
Journal Article
Closed access
MCM. Casato
M. Casato
LPL.P. Pucillo
L.P. Pucillo
Bruno LaganàBruno Laganà
Bruno Laganà
Gloria TalianiGloria Taliani
Gloria Taliani
FGF. Goffredo
F. Goffredo
LBL. Bonomo
L. Bonomo

1 April 2006 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
Gloria TalianiGloria Taliani
Gloria Taliani
GGGiulia Gemignani
Giulia Gemignani
CFCarlo Ferrari
Carlo Ferrari
AAAntonio Aceti
Antonio Aceti
DBDario Bartolozzi
Dario Bartolozzi
NGNonresponder Retreatment Group
Nonresponder Retreatment Group

12 November 2010 in Virology Journal
Verified
Journal Article
Open access
PDF file
CScarolina scagnolari
carolina scagnolari
PZPompea Zingariello
Pompea Zingariello
VJVecchiet Jacopo
Vecchiet Jacopo
CSCarla Selvaggi
Carla Selvaggi
DRDelia Racciatti
Delia Racciatti
GAGuido Antonelli
Guido Antonelli
There have been reports of in-vitro interferon (IFN)-mediated antiviral activity against the hepatitis C virus (HCV) through microRNAs (miRNAs). The main aim of this study was to evaluate the expression of several miRNAs (miR-1, miR-30, miR-128, miR-196, miR-296) in peripheral blood mononuclear cells (PBMCs) from healthy individuals after in vitro IFN-treatment and in PBMCs from patients with chronic hepatitis C (CHC) before and 12 hours after the first injection of pegylated IFN alpha. We demonstrated that expression of these miRNAs could be recorded in PBMCs collected from healthy individuals before and after in-vitro IFN alpha treatment. Our analysis revealed that the levels of expression of all miRNAs investigated in patients with CHC were different to those in healthy individuals. When levels of the miRNAs were measured 12 hours after the first IFN injection, increases in expression levels of IFN-induced miRNAs were observed in 25-50% of patients, depending on the type of miRNA examined. No correlations were observed between HCV viral load, alanine aminotransferase status and expression of miRNA. Together these findings suggest that: (i) IFN alpha in-vitro treatment of PBMCs leads to a transcriptional induction of all miRNAs investigated; (ii) miRNAs can be induced differentially by IFN treatment in patients with HCV. Given the importance of miRNAs in defending the host against virus infections, it is possible that IFN-induced miRNAs may represent an important determinant of the clinical outcome of IFN therapy in HCV infection.

30 July 2016 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
FCFabrizio Conti
Fabrizio Conti
FCFulvia Ceccarelli
Fulvia Ceccarelli
GIGiancarlo Iaiani
Giancarlo Iaiani
Carlo PerriconeCarlo Perricone
Carlo Perricone
AGAlessandra Giordano
Alessandra Giordano
GVGuido Valesini
Guido Valesini
Staphylococcus aureus (SA) is a commensal bacterium representing one of the most important components of the skin microbiome, mostly isolated in the anterior nares. A higher rate of SA nasal colonization in patients affected by Wegener’s granulomatosis and rheumatoid arthritis compared with healthy subjects (HS) has been described. No studies focusing on systemic lupus erythematosus (SLE) are available. We aimed at analyzing the prevalence of SA nasal carriers in an SLE cohort and evaluating correlation between nasal colonization and clinical, laboratory and therapeutic features. We enrolled 84 patients with SLE (number of male/female patients 6/78; mean age 41.3 ± 12.2 years, mean disease duration 142.1 ± 103.8 months) and 154 HS blood donors. Patients with SLE underwent a physical examination and the clinical/laboratory data were collected. All the patients with SLE and the HS received a nasal swab for SA isolation and identification. SA nasal colonization prevalence was 21.4 % in patients with SLE and 28.6 % in HS (P not significant). We analyzed patients with SLE according to the presence (n = 18, SA-positive SLE) or the absence (n = 66, SA-negative SLE) of nasal colonization. Renal involvement was significantly more frequent in SA-positive SLE (11.6 % vs 3.0 %; P = 0.0009). Moreover, the presence of anti-dsDNA, anti-Sm, anti-SSA, anti-SSB, anti-RNP antibodies was significantly higher in SA-positive SLE (P < 0.0001, P = 0.01, P = 0.008, P = 0.03, P = 0.03, respectively). SA colonization is a relatively frequent condition in patients with SLE, with a frequency similar to HS. The presence of SA seems associated with a peculiar SLE phenotype characterized by renal manifestations and autoantibody positivity, confirming the role of the microbiome in disease phenotype.

1 April 2020 in Parasitology International
Verified
Journal Article
Closed access
LVLorenzo Volpicelli
Lorenzo Volpicelli
MAMaurizio De Angelis
Maurizio De Angelis
AMAlessandra Morano
Alessandra Morano
EBElisa Biliotti
Elisa Biliotti
CFCristiana Franchi
Cristiana Franchi
Gloria TalianiGloria Taliani
Gloria Taliani

30 September 2019 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
MSMartina Spaziante
Martina Spaziante
CFCristiana Franchi
Cristiana Franchi
Gloria TalianiGloria Taliani
Gloria Taliani
ADAntonio D’aVolio
Antonio D’aVolio
VPValeria Pietropaolo
Valeria Pietropaolo
MVMario Venditti
Mario Venditti
Here we describe a case of a methicillin-resistant coagulase-negative staphylococci prosthetic valve endocarditis in a patient considered not eligible for valve replacement due to high perioperative mortality risk and who did not tolerate oral antibiotic treatment. Under these circumstances, intravenous long-term chronic suppressive antibiotic therapy with dalbavancin, scheduling the doses using the serum bactericidal activity titers, proved to be safe and effective.